business developments below is a summary of our recent significant business developments : hemophilia b program on october 19 , 2017 , we announced that following multi-disciplinary meetings with the fda and the ema , we plan to expeditiously advance amt-061 , which combines an aav5 vector with the fix-padua mutant , into a pivotal study in mid 2018 for patients with severe and moderately severe hemophilia b. the study is expected to be an open-label , single-dose , multi-center , multi-national trial investigating the efficacy and safety of amt-061 administered to adult patients with severe or moderately severe hemophilia b. we have initiated production of multiple clinical-grade batches of amt-061 in our state-of-the-art lexington , ma manufacturing facility . material is being produced at commercial scale and utilizing current good manufacturing practices ( “ cgmp ” ) . we also announced on october 19 , 2017 , that we have acquired a patent family that broadly covers the fix- 53 padua variant and our use in gene therapy for the treatment of coagulopathies , including hemophilia b. this family includes a patent issued in the u.s. , as well as pending patent applications in europe and canada . huntington program ( amt-130 ) on april 26 , 2017 , we presented new preclinical data on amt-130 amt-130 comprises an aav5 vector carrying a dna cassette encoding an engineered microrna that silences the human huntingtin protein . at the 12th annual chdi huntington 's disease therapeutics conference in malta . data from the study showed widespread and distribution of the aav5 vector throughout the brain and extensive silencing of the human mutant huntingtin gene ( “ htt ” ) in mini pigs , which are among the largest huntington 's disease animal models available for testing . the study demonstrated that a single administration of aav5-mihtt resulted in significant reductions in htt mrna in all regions of the brain transduced by amt-130 , as well as in the cortex . consistent with the reduction in htt mrna , a clear dose-dependent reduction in mutant huntingtin protein levels in the brain was observed , with similar trends in the cerebral spinal fluid . in september 2017 , amt-130 received orphan drug designation from the u.s. food and drug administration . also in september 2017 , we initiated our glp toxicology study in non-human primates with amt-130 . we expect to complete this study and file an ind with the fda by the end of 2018. on october 18 , 2017 , we presented new preclinical data on amt-130 at the european society of gene and cell therapy ( “ esgct ” ) 25th anniversary congress in berlin , germany . data from the study demonstrated that following administration of amt-130 in huntington 's disease mouse models , significant improvements in both motor-coordination and survival were observed , as well as a dose-dependent , sustained reduction in huntingtin protein . manufacturing intellectual property in july 2017 , we were granted a patent from the united states patent and trademark office . the newly issued hermens '627 patent significantly expands our leading intellectual property portfolio related to large-scale , highly reproducible manufacturing of aav in insect cells . this patent , which broadens earlier claims granted in this patent family , is based on research focused on enhancing the genetic stability of the rep78/52 encoding sequences used to produce aav vectors in insect cells . the technology covered in the hermens '627 patent family is currently widely applied in insect cell-based aav manufacturing . aav 5 safety and immunogenicity data on may 12 , 2017 , we presented at the american society of gene & cell therapy 's ( “ asgct ” ) annual meeting in washington , d.c. , new preclinical data demonstrating successful and effective transduction of aav5 in non-human primates with pre-existing anti-aav5 neutralizing antibodies ( “ nabs ” ) . at all observed levels , pre-existing neutralizing antibodies for aav5 did not have a negative impact on the transduction effectiveness of the aav5 vector . this data suggests that patients with pre-existing anti-aav5 nabs may be able to be successfully treated with aav5 gene therapies , such as our product candidates in hemophilia b and in huntington 's disease . this development has the potential to significantly expand the applicability of aav5 gene therapies to nearly all patients , regardless of pre-existing antibodies . in addition , aav5 also appears to have a more favorable immunogenicity profile , with no immune responses detected across three clinical studies involving intravenous administration to 22 patients . we believe these factors make aav5 a highly differentiated , best-in-class vector with the potential to more effectively and safely deliver gene therapies to a greater group of patients in need of treatment . bms collaboration we have made continued progress on our research collaboration with bristol-myers squibb ( “ bms ” ) in congestive heart failure . on august 8 , 2017 , we announced that preliminary data from a study in large animals demonstrated both dna delivery and human s100a1 expression in the myocardium after treatments with product produced from our proprietary insect cell , baculovirus manufacturing process . based on this finding and others , we and bms have advanced the amt-126 , the gene therapy candidate for the treatment of congestive heart failure into further preclinical studies , including a preclinical heart function study in a diseased mini pig model in early 2018 . 54 chiesi collaboration on april 20 , 2017 , we announced that we would not pursue the renewal of the glybera marketing authorization in europe when it is expired on october 25 , 2017. we will be responsible for terminating the phase iv post-approval study . story_separator_special_tag although we do not expect our estimates to be materially different from amounts actually incurred , our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period . recent accounting pronouncements asu 2014-09 : asc 606 revenue from contracts with customers in july 2015 , the fasb issued asu 2015-14 , revenue from contracts with customers : deferral of the effective date ( “ asu 2015-14 ” ) , which deferred the effective date for asu 2014-09 , revenue from contracts with customers ( “ asu 2014-09 ” ) , by one year . asu 2014-09 will supersede the revenue recognition requirements in asc 605 , revenue recognition , and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services . in 2016 , the fasb issued asu 2016-08 , 2016-10 and 2016-12 , which provided further clarification on asu 2014-09. asu 2014-09 is effective for annual reporting periods beginning after december 15 , 2017 , including interim periods within that reporting period , which for the company is january 1 , 2018. asu 2014-09 provides for two implementation methods to us , ( i ) full retrospective application to all periods from january 1 , 2015 onwards for revenue recognized in relation to collaborations ; or ( ii ) application of the standard from january 1 , 2018 , onwards to active collaborations with an adjustment to retained earnings as of december 31 , 2017 , to include the cumulative adjustment to revenue recognized in prior periods in relation to active collaborations . we selected 59 the cumulative effect method to adopt the standard and will not use practical expedients at initial application . we have one active collaboration arrangement with bristol myers squibb ( “ bms ” ) . as a result of the cumulative effect method we will not apply the requirements of asu 2014-09 to any comparative periods presented and therefore the impact assessment applies to bms collaboration agreement only . we are finalizing our evaluation of the impact of adopting this standard . we have considered the new standard and preliminarily expect that the revenue recognition for the existing license will not be materially impacted based on the transfer of the services over the performance obligation . sales-based milestone payments and royalties will continue to be recognized in the statement of comprehensive income when earned . collaboration revenues , which are typically related to reimbursements from collaborators for our performance and costs incurred of research and development services under the respective agreements , are recognized in the statement of comprehensive income on the basis of labor hours valued at a contractually agreed rate and as costs incurred . asu 2016-02 : leases in february 2016 , the fasb issued asu 2016-02 , leases ( “ asu 2016-02 ” ) . the standard amends the existing accounting standards for lease accounting , including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting . asu 2016-02 is effective for annual periods in fiscal years beginning after december 15 , 2019. early adoption is permitted . the new leases standard requires a modified retrospective transition approach for all leases existing at , or entered into after , the date of initial application with an option to use certain transition relief . we expect asu 2016-02 to have a material impact on our consolidated financial statements , primarily from recognition of a right-of-use asset and lease liability in the consolidated balance sheets and a shift of cash outflows from operating activities to financing activities . see note 2 to our consolidate financial statements included in part iv , item 15 , exhibits and financial statement schedules of this annual report on form 10-k for a detailed description of recent accounting pronouncements applicable to our business . results of operations the following table presents a comparison of the twelve months ended december 31 , 2017 , 2016 and 2015. replace_table_token_8_th 60 revenue we recognize total collaboration revenues associated with development activities that are reimbursable by chiesi ( up to the july 2017 termination of the collaboration ) and bms under our respective collaboration agreements . we recognize license revenues associated with the amortization of the non‑refundable upfront payment , target designation fees and research and development milestone payments we have received or might receive from bms . the timing of these cash payments may differ from the recognition of revenue , as revenue is deferred and recognized over the duration of the performance period . we treat other revenue , such as sales milestone payments or service fees , as earned when receivable . our revenue for the years ended december 31 , 2017 , 2016 and 2015 was as follows : replace_table_token_9_th in association with the upfront payments and target designation fees received from bms in the second and third quarters of 2015 , we recognized $ 4.1 million in license revenue during the year ended december 31 , 2017 , compared to $ 3.9 million and $ 2.4 million for the years ended december 31 , 2016 and december 31 , 2015. following the termination of our collaboration with chiesi in july 2017 , we no longer recognize license revenue in association with the upfront fees received in 2013. we recognized $ 0.0 million license revenue during the year ended december 31 , 2017 , compared to $ 1.0 million and $ 1.0 million for the years ended december 31 , 2016 and december 31 , 2015. we recognized our license revenue during the year ended december 31 , 2017 , net of a $ 0.5 million reduction for amounts

sources of liquidity from our first institutional venture capital financing in 2006 through 2017 , we funded our operations primarily through private placements and public offerings of equity securities , convertible and other debt securities and to a lesser extent upfront , target designation or similar payments from our collaboration partners as well as collaboration revenues . on october 27 , 2017 , we completed a follow-on public offering of ordinary shares . we issued and sold 5,000,000 ordinary shares at $ 18.25 per ordinary share , resulting in gross proceeds of approximately $ 91.3 million . the net proceeds to us from this offering were approximately $ 85.3 million , after deducting underwriting discounts and commissions and other offering expenses payable by us . in september 2017 , we established an “ at the market ” equity offering program pursuant to which we can sell up to 5 million ordinary shares at prevailing market prices from time to time . no ordinary shares were issued in accordance with this program during 2017. in april 2015 , we completed our follow‑on public offering raising total gross proceeds of $ 88.5 million and net proceeds of $ 82.5 million after commissions and after deducting share issuance expenses . also in april 2015 , we entered into collaboration agreements with bms , the financial terms of which consist of : · an upfront payment of $ 50.0 million made at the closing of the transaction on may 2015 ; · a $ 15.0 million payment made in july 2015 , following the designation of three additional collaboration targets ; · an initial equity investment of $ 37.6 million for the purchase of 1.1 million ordinary shares , representing 4.9 % of our outstanding shares following such issuance , made in june 2015 at a price of $ 33.84 per share ; · a second equity investment of $ 37.9 million for the purchase of an additional 1.3 million ordinary shares , representing 5.0 % of our outstanding shares following such issuance , made in august 2015 at a price of $ 29.67 per share ; · two warrants to acquire additional equity interests , at a premium to market , to own 14.9


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```sources of liquidity from our first institutional venture capital financing in 2006 through 2017 , we funded our operations primarily through private placements and public offerings of equity securities , convertible and other debt securities and to a lesser extent upfront , target designation or similar payments from our collaboration partners as well as collaboration revenues . on october 27 , 2017 , we completed a follow-on public offering of ordinary shares . we issued and sold 5,000,000 ordinary shares at $ 18.25 per ordinary share , resulting in gross proceeds of approximately $ 91.3 million . the net proceeds to us from this offering were approximately $ 85.3 million , after deducting underwriting discounts and commissions and other offering expenses payable by us . in september 2017 , we established an “ at the market ” equity offering program pursuant to which we can sell up to 5 million ordinary shares at prevailing market prices from time to time . no ordinary shares were issued in accordance with this program during 2017. in april 2015 , we completed our follow‑on public offering raising total gross proceeds of $ 88.5 million and net proceeds of $ 82.5 million after commissions and after deducting share issuance expenses . also in april 2015 , we entered into collaboration agreements with bms , the financial terms of which consist of : · an upfront payment of $ 50.0 million made at the closing of the transaction on may 2015 ; · a $ 15.0 million payment made in july 2015 , following the designation of three additional collaboration targets ; · an initial equity investment of $ 37.6 million for the purchase of 1.1 million ordinary shares , representing 4.9 % of our outstanding shares following such issuance , made in june 2015 at a price of $ 33.84 per share ; · a second equity investment of $ 37.9 million for the purchase of an additional 1.3 million ordinary shares , representing 5.0 % of our outstanding shares following such issuance , made in august 2015 at a price of $ 29.67 per share ; · two warrants to acquire additional equity interests , at a premium to market , to own 14.9
```    
 Suspicious Activity Report : business developments below is a summary of our recent significant business developments : hemophilia b program on october 19 , 2017 , we announced that following multi-disciplinary meetings with the fda and the ema , we plan to expeditiously advance amt-061 , which combines an aav5 vector with the fix-padua mutant , into a pivotal study in mid 2018 for patients with severe and moderately severe hemophilia b. the study is expected to be an open-label , single-dose , multi-center , multi-national trial investigating the efficacy and safety of amt-061 administered to adult patients with severe or moderately severe hemophilia b. we have initiated production of multiple clinical-grade batches of amt-061 in our state-of-the-art lexington , ma manufacturing facility . material is being produced at commercial scale and utilizing current good manufacturing practices ( “ cgmp ” ) . we also announced on october 19 , 2017 , that we have acquired a patent family that broadly covers the fix- 53 padua variant and our use in gene therapy for the treatment of coagulopathies , including hemophilia b. this family includes a patent issued in the u.s. , as well as pending patent applications in europe and canada . huntington program ( amt-130 ) on april 26 , 2017 , we presented new preclinical data on amt-130 amt-130 comprises an aav5 vector carrying a dna cassette encoding an engineered microrna that silences the human huntingtin protein . at the 12th annual chdi huntington 's disease therapeutics conference in malta . data from the study showed widespread and distribution of the aav5 vector throughout the brain and extensive silencing of the human mutant huntingtin gene ( “ htt ” ) in mini pigs , which are among the largest huntington 's disease animal models available for testing . the study demonstrated that a single administration of aav5-mihtt resulted in significant reductions in htt mrna in all regions of the brain transduced by amt-130 , as well as in the cortex . consistent with the reduction in htt mrna , a clear dose-dependent reduction in mutant huntingtin protein levels in the brain was observed , with similar trends in the cerebral spinal fluid . in september 2017 , amt-130 received orphan drug designation from the u.s. food and drug administration . also in september 2017 , we initiated our glp toxicology study in non-human primates with amt-130 . we expect to complete this study and file an ind with the fda by the end of 2018. on october 18 , 2017 , we presented new preclinical data on amt-130 at the european society of gene and cell therapy ( “ esgct ” ) 25th anniversary congress in berlin , germany . data from the study demonstrated that following administration of amt-130 in huntington 's disease mouse models , significant improvements in both motor-coordination and survival were observed , as well as a dose-dependent , sustained reduction in huntingtin protein . manufacturing intellectual property in july 2017 , we were granted a patent from the united states patent and trademark office . the newly issued hermens '627 patent significantly expands our leading intellectual property portfolio related to large-scale , highly reproducible manufacturing of aav in insect cells . this patent , which broadens earlier claims granted in this patent family , is based on research focused on enhancing the genetic stability of the rep78/52 encoding sequences used to produce aav vectors in insect cells . the technology covered in the hermens '627 patent family is currently widely applied in insect cell-based aav manufacturing . aav 5 safety and immunogenicity data on may 12 , 2017 , we presented at the american society of gene & cell therapy 's ( “ asgct ” ) annual meeting in washington , d.c. , new preclinical data demonstrating successful and effective transduction of aav5 in non-human primates with pre-existing anti-aav5 neutralizing antibodies ( “ nabs ” ) . at all observed levels , pre-existing neutralizing antibodies for aav5 did not have a negative impact on the transduction effectiveness of the aav5 vector . this data suggests that patients with pre-existing anti-aav5 nabs may be able to be successfully treated with aav5 gene therapies , such as our product candidates in hemophilia b and in huntington 's disease . this development has the potential to significantly expand the applicability of aav5 gene therapies to nearly all patients , regardless of pre-existing antibodies . in addition , aav5 also appears to have a more favorable immunogenicity profile , with no immune responses detected across three clinical studies involving intravenous administration to 22 patients . we believe these factors make aav5 a highly differentiated , best-in-class vector with the potential to more effectively and safely deliver gene therapies to a greater group of patients in need of treatment . bms collaboration we have made continued progress on our research collaboration with bristol-myers squibb ( “ bms ” ) in congestive heart failure . on august 8 , 2017 , we announced that preliminary data from a study in large animals demonstrated both dna delivery and human s100a1 expression in the myocardium after treatments with product produced from our proprietary insect cell , baculovirus manufacturing process . based on this finding and others , we and bms have advanced the amt-126 , the gene therapy candidate for the treatment of congestive heart failure into further preclinical studies , including a preclinical heart function study in a diseased mini pig model in early 2018 . 54 chiesi collaboration on april 20 , 2017 , we announced that we would not pursue the renewal of the glybera marketing authorization in europe when it is expired on october 25 , 2017. we will be responsible for terminating the phase iv post-approval study . story_separator_special_tag although we do not expect our estimates to be materially different from amounts actually incurred , our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period . recent accounting pronouncements asu 2014-09 : asc 606 revenue from contracts with customers in july 2015 , the fasb issued asu 2015-14 , revenue from contracts with customers : deferral of the effective date ( “ asu 2015-14 ” ) , which deferred the effective date for asu 2014-09 , revenue from contracts with customers ( “ asu 2014-09 ” ) , by one year . asu 2014-09 will supersede the revenue recognition requirements in asc 605 , revenue recognition , and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services . in 2016 , the fasb issued asu 2016-08 , 2016-10 and 2016-12 , which provided further clarification on asu 2014-09. asu 2014-09 is effective for annual reporting periods beginning after december 15 , 2017 , including interim periods within that reporting period , which for the company is january 1 , 2018. asu 2014-09 provides for two implementation methods to us , ( i ) full retrospective application to all periods from january 1 , 2015 onwards for revenue recognized in relation to collaborations ; or ( ii ) application of the standard from january 1 , 2018 , onwards to active collaborations with an adjustment to retained earnings as of december 31 , 2017 , to include the cumulative adjustment to revenue recognized in prior periods in relation to active collaborations . we selected 59 the cumulative effect method to adopt the standard and will not use practical expedients at initial application . we have one active collaboration arrangement with bristol myers squibb ( “ bms ” ) . as a result of the cumulative effect method we will not apply the requirements of asu 2014-09 to any comparative periods presented and therefore the impact assessment applies to bms collaboration agreement only . we are finalizing our evaluation of the impact of adopting this standard . we have considered the new standard and preliminarily expect that the revenue recognition for the existing license will not be materially impacted based on the transfer of the services over the performance obligation . sales-based milestone payments and royalties will continue to be recognized in the statement of comprehensive income when earned . collaboration revenues , which are typically related to reimbursements from collaborators for our performance and costs incurred of research and development services under the respective agreements , are recognized in the statement of comprehensive income on the basis of labor hours valued at a contractually agreed rate and as costs incurred . asu 2016-02 : leases in february 2016 , the fasb issued asu 2016-02 , leases ( “ asu 2016-02 ” ) . the standard amends the existing accounting standards for lease accounting , including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting . asu 2016-02 is effective for annual periods in fiscal years beginning after december 15 , 2019. early adoption is permitted . the new leases standard requires a modified retrospective transition approach for all leases existing at , or entered into after , the date of initial application with an option to use certain transition relief . we expect asu 2016-02 to have a material impact on our consolidated financial statements , primarily from recognition of a right-of-use asset and lease liability in the consolidated balance sheets and a shift of cash outflows from operating activities to financing activities . see note 2 to our consolidate financial statements included in part iv , item 15 , exhibits and financial statement schedules of this annual report on form 10-k for a detailed description of recent accounting pronouncements applicable to our business . results of operations the following table presents a comparison of the twelve months ended december 31 , 2017 , 2016 and 2015. replace_table_token_8_th 60 revenue we recognize total collaboration revenues associated with development activities that are reimbursable by chiesi ( up to the july 2017 termination of the collaboration ) and bms under our respective collaboration agreements . we recognize license revenues associated with the amortization of the non‑refundable upfront payment , target designation fees and research and development milestone payments we have received or might receive from bms . the timing of these cash payments may differ from the recognition of revenue , as revenue is deferred and recognized over the duration of the performance period . we treat other revenue , such as sales milestone payments or service fees , as earned when receivable . our revenue for the years ended december 31 , 2017 , 2016 and 2015 was as follows : replace_table_token_9_th in association with the upfront payments and target designation fees received from bms in the second and third quarters of 2015 , we recognized $ 4.1 million in license revenue during the year ended december 31 , 2017 , compared to $ 3.9 million and $ 2.4 million for the years ended december 31 , 2016 and december 31 , 2015. following the termination of our collaboration with chiesi in july 2017 , we no longer recognize license revenue in association with the upfront fees received in 2013. we recognized $ 0.0 million license revenue during the year ended december 31 , 2017 , compared to $ 1.0 million and $ 1.0 million for the years ended december 31 , 2016 and december 31 , 2015. we recognized our license revenue during the year ended december 31 , 2017 , net of a $ 0.5 million reduction for amounts

